Cargando…
The BRCA Gene in Epithelial Ovarian Cancer
SIMPLE SUMMARY: Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. In the recent years, the germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2) genes are of key importance not only for genetic counseling purposes, but for its therapeutic implicat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909050/ https://www.ncbi.nlm.nih.gov/pubmed/35267543 http://dx.doi.org/10.3390/cancers14051235 |
_version_ | 1784666020054564864 |
---|---|
author | Sánchez-Lorenzo, Luisa Salas-Benito, Diego Villamayor, Julia Patiño-García, Ana González-Martín, Antonio |
author_facet | Sánchez-Lorenzo, Luisa Salas-Benito, Diego Villamayor, Julia Patiño-García, Ana González-Martín, Antonio |
author_sort | Sánchez-Lorenzo, Luisa |
collection | PubMed |
description | SIMPLE SUMMARY: Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. In the recent years, the germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2) genes are of key importance not only for genetic counseling purposes, but for its therapeutic implications, as well as somatic mutations, for the latter. The integration of poly-(ADP ribose) polymerase inhibitors (PARPis) as part of the therapeutic options has changed EOC natural history. ABSTRACT: Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. Germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2) genes have been identified in up to 18% of women diagnosed with EOC, and somatic mutations are found in an additional 7%. Testing of BRCA at the primary diagnosis of patients with EOC is recommended due to the implications in the genomic counseling of the patients and their families, as well as for the therapeutic implications. Indeed, the introduction of poly-(ADP ribose) polymerase inhibitors (PARPis) has changed the natural history of patients harboring a mutation in BRCA, and has resulted in a new era in the treatment of patients with ovarian cancer harboring a BRCA mutation. |
format | Online Article Text |
id | pubmed-8909050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89090502022-03-11 The BRCA Gene in Epithelial Ovarian Cancer Sánchez-Lorenzo, Luisa Salas-Benito, Diego Villamayor, Julia Patiño-García, Ana González-Martín, Antonio Cancers (Basel) Review SIMPLE SUMMARY: Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. In the recent years, the germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2) genes are of key importance not only for genetic counseling purposes, but for its therapeutic implications, as well as somatic mutations, for the latter. The integration of poly-(ADP ribose) polymerase inhibitors (PARPis) as part of the therapeutic options has changed EOC natural history. ABSTRACT: Epithelial ovarian cancer (EOC) is still the most lethal gynecological cancer. Germline alterations in breast cancer 1 (gBRCA1) and breast cancer 2 (gBRCA2) genes have been identified in up to 18% of women diagnosed with EOC, and somatic mutations are found in an additional 7%. Testing of BRCA at the primary diagnosis of patients with EOC is recommended due to the implications in the genomic counseling of the patients and their families, as well as for the therapeutic implications. Indeed, the introduction of poly-(ADP ribose) polymerase inhibitors (PARPis) has changed the natural history of patients harboring a mutation in BRCA, and has resulted in a new era in the treatment of patients with ovarian cancer harboring a BRCA mutation. MDPI 2022-02-27 /pmc/articles/PMC8909050/ /pubmed/35267543 http://dx.doi.org/10.3390/cancers14051235 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sánchez-Lorenzo, Luisa Salas-Benito, Diego Villamayor, Julia Patiño-García, Ana González-Martín, Antonio The BRCA Gene in Epithelial Ovarian Cancer |
title | The BRCA Gene in Epithelial Ovarian Cancer |
title_full | The BRCA Gene in Epithelial Ovarian Cancer |
title_fullStr | The BRCA Gene in Epithelial Ovarian Cancer |
title_full_unstemmed | The BRCA Gene in Epithelial Ovarian Cancer |
title_short | The BRCA Gene in Epithelial Ovarian Cancer |
title_sort | brca gene in epithelial ovarian cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909050/ https://www.ncbi.nlm.nih.gov/pubmed/35267543 http://dx.doi.org/10.3390/cancers14051235 |
work_keys_str_mv | AT sanchezlorenzoluisa thebrcageneinepithelialovariancancer AT salasbenitodiego thebrcageneinepithelialovariancancer AT villamayorjulia thebrcageneinepithelialovariancancer AT patinogarciaana thebrcageneinepithelialovariancancer AT gonzalezmartinantonio thebrcageneinepithelialovariancancer AT sanchezlorenzoluisa brcageneinepithelialovariancancer AT salasbenitodiego brcageneinepithelialovariancancer AT villamayorjulia brcageneinepithelialovariancancer AT patinogarciaana brcageneinepithelialovariancancer AT gonzalezmartinantonio brcageneinepithelialovariancancer |